DelveInsight’s, “Essential Tremor – Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Essential Tremor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Essential Tremor: Overview
Essential tremor (ET) is a progressive, neurological disease characterized by tremor, most often of the hands or arms. A tremor is an involuntary, rhythmic, movement of a body part. Tremor may be seen as involuntary shaking or trembling of the affected area. In individuals with ET, other motor symptoms may be present including an unsteady manner of walking due to an inability to coordinate voluntary movements (ataxia). In some cases, affected individuals may also develop a variety of non-motor symptoms including cognitive impairment, depression or anxiety. ET can occur in childhood or adulthood. The exact, underlying cause of ET is not fully understood. In some cases, the disorder runs in families; in others, it occurs in individuals with no previous family history. The causes of ET are most likely many, which means that several factors, such as genetic and environmental ones, may each play a role in the development of the disorder.
"Essential Tremor - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Essential Tremor pipeline landscape is provided which includes the disease overview and Essential Tremor treatment guidelines. The assessment part of the report embraces, in depth Essential Tremor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Essential Tremor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Essential Tremor R&D. The therapies under development are focused on novel approaches to treat/improve Essential Tremor.
This segment of the Essential Tremor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Essential Tremor Emerging Drugs
SAGE-324: Sage therapeutics
SAGE-324 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). NAS GABAA receptor PAMs bind to both synaptic and extrasynaptic GABAA receptors, enhancing inhibitory activity of the GABAergic system, the major inhibitory neurotransmission system in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system and plays a critical role in maintaining balanced neuronal activity in the brain. GABA dysregulation has been implicated in the pathophysiology of ET. It is currently being evaluated in Phase II stage of development.
PRAX-944: Praxis Precision Medicines
PRAX-944, a potentially differentiated selective small molecule inhibitor of T-type calcium channels, for the treatment of Essential Tremor, or ET. Praxis is currently in the second of two cohorts of its PRAX-944 Phase 2a trial for treatment of essential tremor (ET), evaluating safety and efficacy in patients titrated up to 120 mg per day.
Further product details are provided in the report……..
This segment of the report provides insights about the different Essential Tremor drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 8+ key companies which are developing the therapies for Essential Tremor. The companies which have their Essential Tremor drug candidates in the most advanced stage, i.e. Phase II include, Sage therapeutics.
DelveInsight’s report covers around 8+ products under different phases of clinical development like
Essential Tremor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Essential Tremor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Essential Tremor drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Essential Tremor: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mid Stage Products (Phase II)
SAGE-324: Sage therapeutics
Drug profiles in the detailed report…..
Preclinical Stage Products
TD 567: OB Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Essential Tremor Key Companies
Essential Tremor Key Products
Essential Tremor- Unmet Needs
Essential Tremor- Market Drivers and Barriers
Essential Tremor- Future Perspectives and Conclusion
Essential Tremor Analyst Views
Essential Tremor Key Companies
Appendix
List of Table
Table 1: Total Products for Essential Tremor
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Essential Tremor
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Product
• Sage Therapeutics
• Praxis Precision Medicines
• Cadent Therapeutics
• Jazz Pharmaceuticals
• Praxis Precision Medicines
• Neurocrine Biosciences
• Merz Pharma
• OB Pharmaceuticals
